Compare REGN & HLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | HLT |
|---|---|---|
| Founded | 1988 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8B | 78.3B |
| IPO Year | 1995 | 2013 |
| Metric | REGN | HLT |
|---|---|---|
| Price | $828.50 | $330.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 15 |
| Target Price | ★ $830.16 | $322.13 |
| AVG Volume (30 Days) | 724.3K | ★ 2.1M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.55% | 0.19% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 18.95 | 3.76 |
| Revenue | $5,872,227,000.00 | ★ $12,039,000,000.00 |
| Revenue This Year | $12.45 | $9.82 |
| Revenue Next Year | $10.13 | $8.37 |
| P/E Ratio | ★ $44.01 | $86.87 |
| Revenue Growth | ★ 20.82 | 7.74 |
| 52 Week Low | $541.00 | $253.54 |
| 52 Week High | $847.00 | $358.00 |
| Indicator | REGN | HLT |
|---|---|---|
| Relative Strength Index (RSI) | 73.76 | 53.73 |
| Support Level | $732.04 | $328.66 |
| Resistance Level | N/A | $333.82 |
| Average True Range (ATR) | 19.12 | 6.53 |
| MACD | 1.01 | 1.56 |
| Stochastic Oscillator | 78.77 | 74.28 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Hilton Worldwide Holdings operates 1.36 million rooms across its 27 brands, serving the premium economy through luxury segments. Hampton and Hilton are the two largest brands, representing 27% and 18%, respectively, of the company's total rooms, as of Dec. 31, 2025. Recent brands launched over the past few years include Home2, Curio, Canopy, Spark, Tru, Tempo, LivSmart, and Outset. Additionally, there is a partnership with Small Luxury Hotels of the World and acquisitions of NoMad and Graduate Hotels. Managed and franchised hotels represent the vast majority of adjusted EBITDA, predominantly from the Americas.